Depressive symptoms and presynaptic dopamine function in neuroleptic- naive schizophrenia

Schizophrenia Research

Volumn 35, Issue 1, 1999, Pages 41-50

  Hietala, Jarmo ^a,b   Syvälahti, Erkka ^b,c   Vilkman, Harry ^b,c   Vuorio, Klaus ^d   Räkköläinen, Viljo ^d   Bergman, Jörgen ^e   Haaparanta, Merja ^b   Solin, Olof ^e   Kuoppamäki, Mikko ^c   Eronen, Esa ^b   Ruotsalainen, Ulla ^b   Salokangas, Raimo K R ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b TURKU PET CENTRE   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

^d Turku City Library   (Finland)

^e ÅBO AKADEMI UNIVERSITY   (Finland)

Author keywords

Depression; Dopamine; Positron emission tomography; Schizophrenia; Striatum

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CORPUS STRIATUM; DEPRESSION; DOPAMINE METABOLISM; DOPAMINE RELEASE; FEMALE; HUMAN; MALE; MENTAL DISEASE; NEGATIVE SYNDROME; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC INHIBITION; PRIORITY JOURNAL; RECEPTOR BLOCKING; SCHIZOPHRENIA; SYMPTOMATOLOGY;

ADOLESCENT; ADULT; CORPUS STRIATUM; DEPRESSIVE DISORDER; DIHYDROXYPHENYLALANINE; DOPAMINE; FEMALE; FUNCTIONAL LATERALITY; HUMANS; MALE; PUTAMEN; RECEPTORS, PRESYNAPTIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0345059223     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(98)00113-3     Document Type: Article

References (58)

1. Andreasen N.C., Olsen S.A. Negative v. positive schizophrenia: definition and validation. Arch. Gen. Psychiatry. 39:1982;789-794.
2. Andreasen N.C. Symptoms, signs and diagnosis of schizophrenia. Lancet. 346:1995;477-481.
3. Barnes T.R.E., Curson D.A., Liddle P.F., Patel M. The nature and prevalence of depression in chronic schizophrenic in-patients. Br. J. Psychiatry. 154:1989;486-491.
4. Baxter L.R., Schwartz J.M., Phelps M.E., Mazziotta J.C., Guze B.H., Selin C.E., Gerner R.H., Sumida R.M. Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch. Gen. Psychiatry. 46:1989;243-250.
5. Bench C.J., Friston K.J., Brown R.G., Frackowiak R.S.J., Dolan R.J. Regional cerebral blood flow in depression measured by positron emission tomography: the relationship with clinical dimensions. Psychol. Med. 23:1993;579-590.
6. Benkelfat, C., Nishizawa, S., Kuwabara, H., Lal, S., Chouinard, G., Cumming, P., Labelle, A., Juuber, R., Bruce, K., Gjedde, A., 1996. Brain dopa-decarboxylase (DDC) activity in unmedicated schizophrenic patients. In: ACNP Abstracts, 35th Annual Meeting, San Juan, Puerto Rico, 9-13 December, p. 188.
7. 18F ]-fluoride J. Label Comp. Radiopharmacol. XXXV:1994;476-477.
8. Bermanzohn P.C., Siris S.G. Akinesia: a syndrome common to Parkinsonism, retarded depression and negative symptoms of schizophrenia. Compr. Psychiatry. 33:1992;221-232.
9. Bilder R.M., Wu H., Bogerts B., Degreef G., Ashtari M., Alvir J.M.J., Snyder P.J., Lieberman J.A. Absence of regional hemispheric volume asymmetries in first-episode schizophrenia. Am. J. Psychiatry. 151:1994;1437-1447.
10. Bodkin J.A., Cohen B.M., Salomon M.S., Cannon S.E., Zornberg G.L., Cole J.O. Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication. A pilot study examining the role of dopamine. J. Nerv. Ment. Dis. 184:1996;295-301.
11. Brown A.S., Gershon S. Dopamine and depression. J. Neural Transm. 91:1993;75-109.
12. Caldwell C.B., Gottesman I.I. Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophr. Bull. 16:1990;571-589.
13. Carlsson A., Lindquist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. Toxicol. 20:1963;140-144.
14. Chatterjee A., Chakos M., Koreen A., Geisler S., Sheitman B., Woerner M., Kane J.M., Alvir J., Lieberman J. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am. J. Psychiatry. 152:1995;1724-1729.
15. Connell, P. (1958) Amphetamine psychosis. Maudsley Monograph, vol. 5. Chapman & Hall, London.
16. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of neuroleptic drugs. Science. 192:1976;481-483.
17. Crow T.J. Molecular pathology of schizophrenia: more than one disease process? Br. Med. J. 280:1980;66-68.
18. Cummings J.L. Depression and Parkinson's disease. Am. J. Psychiatry. 149:1992;443-450.
19. Dao-Castellana M.H., Paillere-Martinot M.-L., Hantraye P., Attar-Levy D., Remy P., Crouzel C., Artiges E., Feline A., Syrota A., Martinot J.L. Presynaptic dopamnergic function of schizophrenic patients. Schizophr. Res. 23:1997;167-174.
20. Drevets W.C., Videen T.O., Price J.L., Prekorn S.H., Carmichael S.T., Raichle M.E. A functional anatomical study of unipolar depression. J. Neurosci. 12:1992;3628-3641.
21. D'Haenen H.A., Bossuyt A. Dopamine D2 receptors in depression measured with single photon emission computed tomography. Biol. Psychiatry. 35:1994;128-132.
22. Ebert D., Feistel H., Loew T., Pirner A. Dopamine and depression - striatal dopamine D2 receptor SPEC before and after antidepressant therapy. Psychopharmacology. 126:1996;91-94.
23. 2 dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch. Gen. Psychiatry. 45:1988;71-76.
24. Gawin F.H. Neuroleptic reduction of cocaine-induced paranoia but not euphoria? Psychopharmacology. 90:1986;142-143.
25. Green M.F., Neuchterlein K.H., Ventura J., Mintz J. The temporal relationship between depressive and psychotic symptoms in recent-onset schizophrenia. Am. J. Psychiatry. 147:1990;179-182.
26. Hietala J., Syvälahti E., Vuorio K.et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet. 346:1995;1130-1131.
27. Jablensky A., Sartorius N., Ernberg G., Anker M., Korten A., Cooper J.E., Day R., Bertelsen A. Schizophrenia: manifestations, incidence and course in different cultures: a World Health Organization Ten Country Study. Psychol. Med. 22(Suppl. 20):1992;1-97.
28. Johnson D.A.W. Studies of depressive symptoms in schizophrenia II: a two-year longitudinal study of symptoms. Br. J. Psychiatry. 139:1981;93-96.
29. Kay S.R., Sevy S. Pyramidical model of schizophrenia. Schizophr. Bull. 16:1990;537-545.
30. Koreen A.R., Siris S.G., Chakos M., Alvir J., Mayerhoff D., Lieberman J. Depression in first-episode schizophrenia. Am. J. Psychiatry. 150:1993;1643-1648.
31. Leff, J., 1990. Depressive symptoms in the course of schizophrenia. In: DeLisi, L.E. (Ed.), Depression in Schizophrenia. American Psychiatric Press, Washington, pp. 1-23.
32. Liddle P., Friston K.J., Frith C.D., Hirsch S.R., Jones T., Frackowiak R.S.J. Patterns of cerebral blood flow in schizophrenia. Br. J. Psychiatry. 160:1992;179-186.
33. Lindenmayer J.-P., Bernstein-Hyman R., Grochowski S. Five-factor model of schizophrenia. Initial validation. J. Nerv. Ment. Dis. 182:1994;631-638.
34. Lindenmayer J.-P., Grochowski S., Hyman R.B. Five factor model of schizophrenia: replication across samples. Schizophr. Res. 14:1995;229-234.
35. Martinot J.L., Hardy P.H., Feline A., Huret J.D., Mazoyer B., Attar-Levy D., Pappata S., Syrota A. Left prefrontal glucose hypometabolism in the depressed state: a confirmation. Am. J. Psychiatry. 1476:1990;1313-1317.
36. McCreadie R.G., Thara R., Kamath S., Padmavathy R., Latha S., Mathrubootham N., Menon M.S. Abnormal movements in never-medicated Indian patients with schizophrenia. Br. J. Psychiatry. 168:1996;221-226.
37. McGlashan T.H., Carpenter W.T. Jr. Postpsychotic depression in schizophrenia. Arch. Gen. Psychiatry. 33:1976;231-239.
38. Meltzer H.Y., Sommers A.A., Luchins D.J. The effect of neuroleptics and other psycotropic drugs on negative symptoms in schizophrenia. J. Clin. Psychopharmacol. 6:1986;329-338.
39. Meltzer H.Y., Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am. J. Psychiatry. 152:1995;183-190.
40. Patlak C.S., Blasberg R.G., Fernstermacher J.D. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J. Cereb. Blood Flow Metab. 3:1983;1-7.
41. Pearlson G.D., Wong D.F., Tune L.E., Ross C.A., Chase G.A., Links J.M., Dannals R.F., Wilson A.A., Ravert H.T., Wagner H.N. Jr., DePaulo R. In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder. Arch. Gen. Psychiatry. 52:1995;471-477.
42. Pellizari C.A., Chen G.T.Y., Spelbring D.R., Weichselbaum R.r., Chen C.T. Accurate three dimensional registration of CT, PET and/or MRI images of the brain. J. Comput. Assisted Tomogr. 13:1989;20-26.
43. Randrup I., Munkvad I. Special antagonism of amphetamine-induced abnormal behaviour. Psychopharmacologia. 7:1965;416-422.
44. Reith J., Benkelfat C., Sherwin A., Yasuhara Y., Kuwabara H., Andermann F., Bachneff S., Cumming P., Diksic M., Dyve S.E., Etienne P., Evans A.C., Lal S., Shevell M., Savard G., Wong D.F., Chouinard G., Gjedde A. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc. Natl. Acad. Sci. USA. 91:1994;11651-11654.
45. Salokangas R.K.R. Structure of schizophrenic symptomatology and its changes over time. Prospective factor analytic study. Acta Psychiatr. Scand. 95:1997;32-39.
46. Seeman P., Lee T., Chau-Wong M., Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 261:1976;717-719.
47. Sherer M.A., Kumor K.M., Cone E.J., Jaffe J.H. Suspiciousness induced by four-hour intravenous infusions of cocaine. Preliminary findings. Arch. Gen. Psychiatry. 45:1988;673-677.
48. Silbersweig D.A., Stern E., Frith C., Cahill C., Holmes A., Grootonk S., Seaward J., McKenna P., Chua S.E., Schnorr L., Jones T., Frackowiak R. A functional neuroanatomy of hallucinations in schizophrenia. Nature. 378:1995;176-179.
49. Silverstone T. Response to bromocriptine distinguishes bipolar and unipolar depression. Lancet. 1:1984;903-904.
50. Siris S.G., Adan F., Cohen M., Mandeli J., Aronson A., Casey E. Postpsychotic depression and negative symptoms: an investigation of syndromal overlap. Am. J. Psychiatry. 145:1988;1532-1537.
51. Sobin C., Sackeim H.A. Psychomotor symptoms of depression. Am. J. Psychiatry. 154:1997;4-17.
52. Starkstein S., Robinson R.G., Price T.R. Comparison of cortical and subcortical lesions in the production of poststroke mood disorders. Brain. 110:1987;1045-1059.
53. Swerdlow N.R., Koob G.F. Dopamine, schizophrenia, mania and depression: toward a unified hypothesis of cortico-striato-pallido-thalamic function. Behav. Brain Sci. 10:1987;197-245.
54. Tiihonen J., Hari R., Naukkarinen H., Rimon R., Jousmäki V., Kajola M. Auditory hallucinations may modify activity of the human auditory cortex. Am. J. Psychiatry. 149:1992;255-257.
55. van Rossum J.M. The significance of dopamine receptor blockade for the mechanism of action of neuroleptic drugs. Arch. Int. Pharmacodyn. Ther. 160:1966;492-494.
56. van Rossum, J.M., 1967. The significance of dopamine receptor blockade for the action of neuroleptic drugs. In: Brill, H., Cole, J.O., Deniker, P., Hippius, H., Bradley, P.B. (Eds.), Proceedings of the Fifth CINP. Excerpta Medica, Amsterdam, pp. 321-329.
57. Weinberger D.R. Schizophrenia: from neuropathology to neurodevelopment. Lancet. 346:1995;552-557.
58. Willner, P., 1995. Dopaminergic mechanisms in depression and mania. In: Bloom, F.E., Kupfer, D.J., (Eds.), Psychopharmacology: the Fourth Generation of Progress. Raven Press, New York, pp. 921-931.